NASDAQ : AKAN
Akanda Corp. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Last price 1.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.75M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.75M |
| Enterprise Value | 20.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.39M |
| Shares Outstanding | 2.64M |
| Shares Change (YoY) | +2,822.55% |
| Shares Change (QoQ) | +633.95% |
| Owned by Insiders (%) | 1.39% |
| Owned by Institutions (%) | 0.02% |
| Float | 2.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.14 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 31.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.22 |
| Quick Ratio | 0.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.71 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -82.13% |
| Return on Invested Capital (ROIC) | -179.40% |
| Return on Capital Employed (ROCE) | 137.44% |
| Weighted Average Cost of Capital (WACC) | 17.14% |
| Revenue Per Employee | $14,402 |
| Profits Per Employee | -$1.11M |
| Employee Count | 46 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 14.18 |
| 52-Week Price Change | -97.25% |
| 50-Day Moving Average | 2.50 |
| 200-Day Moving Average | 8.38 |
| Relative Strength Index (RSI) | 24.09 |
| Average Volume (20 Days) | 376,535 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 52,279 |
| Short Previous Month | 44,862 |
| Short % of Shares Out | 1.98% |
| Short % of Float | 2.19% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 662,469 |
| Gross Profit | -79,432 |
| Operating Income | -8.31M |
| Pretax Income | -52.21M |
| Net Income | -51.04M |
| EBITDA | -7.91M |
| EBIT | -8.31M |
| Loss Per Share | -$64.96 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 755,238 |
| Total Debt | 18.57M |
| Net Cash | -17.82M |
| Net Cash Per Share | -$6.75 |
| Equity (Book Value) | -16.47M |
| Book Value Per Share | -19.37 |
| Working Capital | -9.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.55M |
| Capital Expenditures | -2.50M |
| Depreciation & Amortization | 401,718 |
| Net Borrowing | 18.97M |
| Free Cash Flow | -12.05M |
| FCF Per Share | -$4.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | -11.99% |
| Operating Margin | -1,254.54% |
| Pretax Margin | -7,880.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2,822.55% |
| Shareholder Yield | -2,822.55% |
| Earnings Yield | -6,246.20% |
| FCF Yield | -439.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 13, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:4.5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -29.64 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |